Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Int J Drug Policy. 2017 Mar 21;42:63–70. doi: 10.1016/j.drugpo.2017.02.009

Figure 1.

Figure 1

Top: Proportion (95% CI) of participants engaged in antiretroviral therapy care at each follow-up period, stratified by ≥daily cannabis use. Bottom: Proportion (95% CI) of antiretroviral therapy-exposed participants reaching viral suppression at each follow-up period, stratified by ≥daily cannabis use.